Analysed RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) News Sources
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
09-04-2026
yahoo.com
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments
05-04-2026
yahoo.com
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
01-04-2026
yahoo.com
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
26-03-2026
yahoo.com
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity
22-03-2026
yahoo.com
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch
22-03-2026
marketbeat.com
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide
22-03-2026
marketbeat.com
What is the current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The current price of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is $84.92.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is $-2.8.
RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) since the previous trading day is -3.192%.
What is the most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent average sentiment score for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)?
The most recent sentiment for RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ) is .
SEC-8K** Filing Available For RHYTHM PHARMACEUTICALS INC (RYTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.